About US
Contact us
-
CSL confirms Fluvax manufacturing tied to convulsions in childrenIf it were not so serious, the FDA could be telling Australian vaccinemaker CSL"I told you so," after a two-year study apparently confirmed what the agency suggested in a warning letter in 2011: CSL's2012/6/20
-
Pfizer expects to wrap up Prempro suits for $1.2B totalThe price tag Pfizer's ($PFE) Prempro settlements is now in. The drugmaker has paid $896 million to wrap up about 60% of the patient lawsuits, Bloomberg reports. That's about 6,000 cases, all alleging2012/6/19
-
No overtime for pharma reps, Supreme Court saysThe Supreme Court has spoken to pharma reps. In a split decision, the justices ruled that drugmakers don't have to pay overtime to salespeople. It's a landmark ruling that will send a lot of lawsuits2012/6/19
-
Merck loses a patent ruling on blockbuster NasonexEven as the clock is ticking down on the patent for its super blockbuster Singulair, Merck ($MRK) got smacked Friday with a negative decision in its battle with genericmaker Apotex overMerck's blockbu2012/6/18
-
Should FDA's standards enforcement be blamed for drug shortages?A House committee report blames FDA oversight for the current epidemic of drug shortages. Rep. Darrell Issa, chairman of the House Oversight Committee, complains that warning letters increased as Pres2012/6/18
-
Regeneron stock falls on new AMD treatment studyRegeneron ($REGN), which makes the new wet AMD treatment Eylea, saw its stock falter after a small drugmaker unveiled data from a study testing its AMD treatment in combination with Eylea rival Lucent2012/6/15
-
Who'll be the biggest drugmaker of them all?Who's ready for the latest Big Pharma line-up? Prepare for some big changes: Pfizer ($PFE) will lose its first-up position in a few years to Novartis ($NVS), EvaluatePharma figures, as Sanofi ($SNY) a2012/6/15
-
Drugmakers warn German pricing is killing innovationAs economies have wilted in Europe, Germany has been all about austerity and how that is the only way to cure the E.U.'s financial woes. But the backlash from drugmakers to German drug pricing has bec2012/6/14
-
Merck plots FDA app as sleep drug aces new trialArmed with new Phase III data on its potential sleep drug suvorexant, Merck ($MRK) plans to ask FDA to approve the new product later this year. One big selling point: 90% of patients didn't feel sleep2012/6/14
-
Supreme Court to put Amgen shareholders' class action on trialTwo types of shareholder lawsuits. Two significant developments that promise to affect future shareholder suits. On the one hand, the U.S. Supreme Court has agreed to weigh a class-action suit against2012/6/13